This site is intended for healthcare professionals

Predstavenie titulu

Novinky z tohtoročného najvýznamnejšieho európskeho stretnutia hematológov 2017

Originálny názov:
Novinky z tohtoročného najvýznamnejšieho európskeho stretnutia hematológov

Dátum vydania: 10/2017


Formát: 210×270 mm

Počet strán: 112

Väzba: V1 ?Listy jsou spojeny sponkou ve hřbetu

Jazyk: Slovenčina

Náhľad PDF


Anotácia

Toto vydanie Event Reportu zhŕňa dianie na 22. kongrese Európskej hematologickej spoločnosti, ktoré sa konalo v júni 2017 v španielskom Madride. Pôvodné informácie zhŕňajú to najdôležitejšie, čo bolo prebraté v sekciách: anémia, chronická myelocytová leukémia, myelodysplastický syndróm, trombocytopénia, myeloproliferatívna neoplázia, chronická myeloidná leukémia, akútna myeloblastová leukémia a mnohopočetný myelóm. Jednotlivé informácie dopĺňajú vybrané abstrakty.



Obsah

22. KONGRES EURÓPSKEJ HEMATOLOGICKEJ ASOCIÁCIE (EHA). MADRID 22. – 25. 6. 2017
Eva BOJTÁROVÁ
 
TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015
 
EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
 
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
 
Chronická lymfocytová leukémia: novinky z kongresu
Mikuláš HRUBIŠKO
 
LIEČBA, EKONOMICKÝ A SOCIÁLNY ÚČINOK SUBKUTÁNNE PODÁVANÉHO RITUXIMABU PRI LYMFOPROLIFERATÍVNYCH MALIGNITÁCH – MAB SC
 
THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR (BCR) CROSS-TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
 
IS FCR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS?
 
BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
 
IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP
 
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
 
Myelodysplastický syndróm
Farkaš Firas
 
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
 
DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE
 
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
 
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS
 
Optimalizácia liečby imúnnej trombocytopénie a nové stratégie liečby trombocytopénie pri aplastickej anémii a myelodysplastickom syndróme
Angelika Bátorová
 
REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY
 
TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
 
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
 
IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?
 
Myeloproliferatívna neoplázia: novinky z kongresu
Antónia Hatalová
 
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
 
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
 
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
 
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
Hana Klamová
 
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
 
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
 
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
 
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
 
Akútna myeloblastová leukémia
Martin Mistrík
 
VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION
 
RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
 
ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO REQUIRE TWO COURSES OF INDUCTION THERAPY TO ACHIEVE COMPLETE REMISSION (CR) SHOULD UNDERGO ALLOGENEIC TRANSPLANT (ALLO-SCT) DURING THE FIRST CR
 
QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
 
MNOHOPOČETNÝ MYELÓM
Zdenka Štefániková
 
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
 
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
 
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
 
POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
 

Tiráž

Vydavateľ: We Make Media Slovakia s.r.o. | Konateľka: MUDr. Ivana Kaderková | Adresa: Bárdošova 2/A, 831 01 Bratislava, Slovenská republika | Tel.: +421 948 422 117 | E-mail: info@wemakemedia.sk | www.wemakemedia.sk
Zodpovedná redaktorka: Veronika Lazarová | Jazyková redaktorka: Mgr. Anetta Letková
Zlom a grafická úprava: We Make Media Slovakia s.r.o. | ISBN: 978 – 80 – 972221 – 5 – 4 | Vyšlo: október 2017

Akékoľvek kopírovanie a šírenie celého obsahu alebo časti tohto časopisu, či už v tlačenej, alebo elektronickej podobe, je bez výslovného súhlasu vydavateľa prísne zakázané.
Vychádza 1× ročne | 1. ročník | V publikácii boli s povolením Európskej hematologickej asociácie použité texty a fotografie zo zdroja:
https://www.ehaweb.org/. Texts and photos from the source https://www.ehaweb.org/ are used with permission of the European Hematology Association. All rights reserved. © 2017 European Hematology Association.



Partneři projektu